NEWBRY Stock Overview
Operates as hybrid pharmaceutical company in Sweden, and Scandinavian market.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Newbury Pharmaceuticals AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.54 |
| 52 Week High | SEK 6.24 |
| 52 Week Low | SEK 2.40 |
| Beta | 1.57 |
| 11 Month Change | 6.63% |
| 3 Month Change | 15.69% |
| 1 Year Change | -11.72% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| NEWBRY | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 0.6% | -5.3% | -6.7% |
| 1Y | -11.7% | 70.7% | 9.9% |
Return vs Industry: NEWBRY underperformed the Swedish Pharmaceuticals industry which returned 70.7% over the past year.
Return vs Market: NEWBRY underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
| NEWBRY volatility | |
|---|---|
| NEWBRY Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: NEWBRY has not had significant price volatility in the past 3 months.
Volatility Over Time: NEWBRY's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 5 | Lars Minor | www.newburypharma.com |
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden, and Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. The company was incorporated in 2020 and is based in Lund, Sweden.
Newbury Pharmaceuticals AB (publ) Fundamentals Summary
| NEWBRY fundamental statistics | |
|---|---|
| Market cap | SEK 85.88m |
| Earnings (TTM) | -SEK 21.90m |
| Revenue (TTM) | SEK 18.53m |
4.6x
P/S Ratio-3.9x
P/E RatioIs NEWBRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEWBRY income statement (TTM) | |
|---|---|
| Revenue | SEK 18.53m |
| Cost of Revenue | SEK 10.88m |
| Gross Profit | SEK 7.66m |
| Other Expenses | SEK 29.55m |
| Earnings | -SEK 21.90m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
Oct 09, 2024
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 41.32% |
| Net Profit Margin | -118.15% |
| Debt/Equity Ratio | 0% |
How did NEWBRY perform over the long term?
See historical performance and comparison